COMPANY

Nektar Therapeutics

HQ: San Francisco, CA source · nektar.com ↗ · West Coast

Keywords: immunology Moderate-to-Severe Atopic Dermatitis Colorectal Cancer Melanoma Renal Cell Carcinoma Head and Neck Squamous Cell Carcinoma Non-Hodgkin Lymphoma Systemic Lupus Erythematosus Breast Cancer Non Small Cell Lung Cancer Triple Negative Breast Cancer Low Back Pain Chronic Pain Alopecia Areata Relapsed/Refractory Diffuse Large B-cell Lymphoma Covid-19 Coronavirus Disease 2019 Atopic Dermatitis Psoriasis Ulcerative Colitis Multiple Myeloma Indolent Non-Hodgkin Lymphoma Melanoma Stage III Melanoma Stage IV Melanoma (Skin) Metastasis Metastatic Renal Cell Carcinoma Urinary Bladder Neoplasm Neoplasm Metastasis Urothelial Carcinoma HR+/HER2- Breast Cancer Gastric Cancer Merkel Cell Carcinoma Sarcoma Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer Osteoarthritis of the Knee Protocol Specific Unspecified Adult Solid Tumor Ovarian Cancer Moderate to Severe Chronic Pain

Location: San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$825.0MRaised (2 yrs)39Trials (company is sponsor)

Timeline

Aug 7, 2026 Trial start 3: A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis source ↗
Jun 29, 2026 Trial start 3: A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis source ↗
Apr 21, 2026 Raise Follow-on offering: $325M (total, as published), announced Apr 21, 2026. Source: SEC filing. source ↗
Feb 11, 2026 Raise Follow-on offering: $400M (total, as published), announced Feb 11, 2026. Source: SEC filing. source ↗
Jul 1, 2025 Raise Follow-on offering: $100M (total, as published), announced Jul 1, 2025. Source: SEC filing. source ↗
Apr 2, 2024 Trial start 2: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) source ↗
Nov 15, 2023 Trial start 2: A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis source ↗
Dec 23, 2022 Trial start Phase 2/Phase 3: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma source ↗
Oct 5, 2022 Trial start I: A Phase I Study of LY3471851 in Healthy Participants source ↗
Mar 9, 2022 Trial start Phase 2/Phase 3: BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) source ↗
Aug 16, 2021 Trial start Phase 1: A Single-Dose Study of LY3471851 in Healthy Participants source ↗
Mar 22, 2021 Trial start Phase 2: A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) source ↗
Nov 13, 2020 Trial start Phase 1: A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 source ↗
Oct 30, 2020 Trial start Phase 1/Phase 2: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors source ↗
Aug 19, 2020 Trial start Phase 2: A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) source ↗
Jul 27, 2020 Trial start Phase 3: Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence source ↗
Dec 4, 2019 Trial start Phase 1: A Study of LY3471851 in Participants With Eczema source ↗
Nov 26, 2019 Trial start Phase 1: A Study of LY3471851 in Participants With Psoriasis source ↗
Oct 29, 2019 Trial start Phase 1: A Study of LY3471851 in Healthy Participants source ↗
Oct 7, 2019 Trial start Phase 1: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma source ↗
2019-08 Trial start Phase 1: A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab source ↗
Apr 29, 2019 Trial start Phase 2: A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer source ↗
Dec 18, 2018 Trial start Phase 3: A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozan source ↗
Oct 22, 2018 Trial start Phase 1: A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users. source ↗
Apr 18, 2018 Trial start Phase 1: A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) source ↗

Showing 25 of 42 dated events.

Upcoming milestones

2028-05 (ESTIMATED) · 3 · A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis · NCT07690371
2028-06 (ESTIMATED) · 3 · A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis · NCT07711418

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $825.0M. Last 2 years.

Apr 21, 2026 Follow-on offering: $325M (total, as published), announced Apr 21, 2026. Source: SEC filing. source ↗
Feb 11, 2026 Follow-on offering: $400M (total, as published), announced Feb 11, 2026. Source: SEC filing. source ↗
Jul 1, 2025 Follow-on offering: $100M (total, as published), announced Jul 1, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 39

Record	Title	Phase	Status	Start	Primary completion
NCT06340360	A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)	2	Completed	Apr 2, 2024	Nov 26, 2025 (actual)
NCT07690371	A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis	3	Recruiting	Jun 29, 2026	2028-05 (estimated)
NCT07711418	A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis	3	Recruiting	Aug 7, 2026	2028-06 (estimated)
NCT06136741	A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis	2	Active, not recruiting	Nov 15, 2023	May 6, 2025 (actual)
NCT04616196	Study of NKTR 255 in Combination With Cetuximab in Solid Tumors	Phase 1/Phase 2	Completed	Oct 30, 2020	Mar 30, 2023 (actual)
NCT05664217	NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma	Phase 2/Phase 3	Terminated	Dec 23, 2022	May 22, 2024 (actual)
NCT04433585	A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)	Phase 2	Completed	Aug 19, 2020	Jan 10, 2023 (actual)
NCT04646044	A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19	Phase 1	Completed	Nov 13, 2020	May 11, 2021 (actual)
NCT04081350	A Study of LY3471851 in Participants With Eczema	Phase 1	Completed	Dec 4, 2019	Jun 24, 2022 (actual)
NCT04119557	A Study of LY3471851 in Participants With Psoriasis	Phase 1	Completed	Nov 26, 2019	Jul 21, 2021 (actual)
NCT04380324	A Study of NKTR-358 (LY3471851) in Healthy Participants	Phase 1	Completed	Mar 19, 2017	Jan 20, 2019 (actual)
NCT03556007	A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)	Phase 1	Completed	Apr 18, 2018	Aug 29, 2019 (actual)
NCT04998487	A Single-Dose Study of LY3471851 in Healthy Participants	Phase 1	Completed	Aug 16, 2021	Jul 6, 2022 (actual)
NCT04133116	A Study of LY3471851 in Healthy Participants	Phase 1	Completed	Oct 29, 2019	Mar 6, 2020 (actual)
NCT05565729	A Phase I Study of LY3471851 in Healthy Participants	I	Completed	Oct 5, 2022	Feb 23, 2023 (actual)
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Phase 2	Terminated	Mar 22, 2021	Aug 9, 2022 (actual)
NCT04136756	NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma	Phase 1	Completed	Oct 7, 2019	Apr 24, 2023 (actual)
NCT04410445	Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence	Phase 3	Terminated	Jul 27, 2020	Sep 22, 2022 (actual)
NCT02915744	A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine	Phase 3	Completed	2016-11	2020-07 (actual)
NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	Phase 3	Terminated	Dec 18, 2018	Jan 7, 2022 (actual)
NCT03785925	A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer	Phase 2	Completed	Apr 29, 2019	Feb 9, 2022 (actual)
NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors	Phase 1/Phase 2	Completed	Dec 19, 2016	Apr 28, 2022 (actual)
NCT03138889	Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2	Terminated	Jun 9, 2017	Jul 5, 2022 (actual)
NCT03435640	REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies	Phase 1/Phase 2	Terminated	Mar 15, 2018	May 9, 2022 (actual)
NCT04969861	BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)	Phase 2/Phase 3	Terminated	Mar 9, 2022	Apr 22, 2022 (actual)
NCT01619839	A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain	2	Completed	2012-06	2013-08 (actual)
NCT02869295	A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors	1	Completed	2015-12	Oct 31, 2018 (actual)
NCT00598975	NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)	2	Completed	2008-02	2009-05 (actual)
NCT00806156	Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer	Phase 2	Completed	2008-10	2012-10 (actual)
NCT00856375	NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer	Phase 2	Completed	2008-12	2014-07 (actual)
NCT01457118	An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies	Phase 2	Completed	2011-10	2017-08 (actual)
NCT03802227	A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.	Phase 1	Terminated	Oct 22, 2018	Dec 17, 2019 (actual)
NCT04955262	A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab	Phase 1	Withdrawn	2019-08	2021-06 (estimated)
NCT02367820	Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain	Phase 3	Completed	Apr 14, 2015	2017-12 (actual)
NCT01492101	The BEACON Study (Breast Cancer Outcomes With NKTR-102)	Phase 3	Completed	2011-12	2016-04 (actual)
NCT02362672	Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain	Phase 3	Completed	Mar 11, 2015	2016-12 (actual)
NCT00802945	Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer	Phase 2	Completed	2008-10	2011-10 (actual)
NCT01991678	A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)	Phase 1	Completed	2013-11	2017-05 (actual)
NCT01976143	A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety	Phase 1	Completed	2014-02	2016-06 (actual)